

WISP2 Antibody (monoclonal) (M09)

Mouse monoclonal antibody raised against a full length recombinant WISP2.

Catalog # AT4540a

Product Information

Application	WB, IP
Primary Accession	O76076
Other Accession	BC017782
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2a Kappa
Clone Names	3D10
Calculated MW	26825

Additional Information

Gene ID	8839
Other Names	WNT1-inducible-signaling pathway protein 2, WISP-2, CCN family member 5, Connective tissue growth factor-like protein, CTGF-L, Connective tissue growth factor-related protein 58, WISP2, CCN5, CT58, CTGFL
Target/Specificity	WISP2 (AAH17782.1, 24 a.a. ~ 250 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IP~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	WISP2 Antibody (monoclonal) (M09) is for research use only and not for use in diagnostic or therapeutic procedures.

Background


This gene encodes a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like (CT) domain. The encoded protein lacks the CT domain which is implicated in dimerization and heparin binding. It is 72% identical to the mouse protein at the amino acid level. This gene may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. Its expression in colon tumors is reduced while the other two WISP members are overexpressed in colon tumors. It is expressed at high levels in bone tissue,

and may play an important role in modulating bone turnover.


References

Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis. Pasmant E, et al. J Neuropathol Exp Neurol, 2010 Jan. PMID 20010302. High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men. Yerges LM, et al. J Bone Miner Res, 2009 Dec. PMID 19453261. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Banerjee S, et al. Cancer Res, 2008 Sep 15. PMID 18794149. Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Dhar G, et al. Cancer Res, 2008 Jun 15. PMID 18559502. Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Fritah A, et al. Mol Cell Biol, 2008 Feb. PMID 18070926.

Images




Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (50.71 KDa) .



Western Blot analysis of WISP2 expression in transfected 293T cell line by WISP2 monoclonal antibody (M09), clone 3D10.

Lane 1: WISP2 transfected lysate (26.8 KDa).
Lane 2: Non-transfected lysate.



Immunoprecipitation of WISP2 transfected lysate using anti-WISP2 monoclonal antibody and Protein A Magnetic Bead ([U0007](#)), and immunoblotted with WISP2 MaxPab rabbit polyclonal antibody.